Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procrit Early vs Standard Dosing in Cancer Anemia
NCT00210600Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2005
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
A Phase 2 trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Started May 2005; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00210600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210600.